Document
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report:  June 14, 2018
(Date of earliest event reported)
 
 


BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)


 
 
 
 
 

Commission File Number: 1-7928
 
 
 
 
Delaware
 
94-1381833
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)

1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)

(510) 724-7000
(Registrant’s telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company      o
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     o



 
ITEM 5.07
Submission of Matters to a Vote of Security Holders.

Bio-Rad Laboratories, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 14, 2018. The matters voted upon at the meeting and the results of those votes are set forth below.
 
 
 
 
 
 
 
1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:
 
 
 
 
 
 
 
Class of
 
 
 
 
 
Common Stock
Votes
Votes
Votes
Broker
 
 to Elect
 for
Against
Abstaining
 Non-Votes
 
 
 
 
 
 
Melinda Litherland
Class A
19,440,910

755,808

8,309
 
1,776,576

Arnold A. Pinkston
Class A
19,697,088

501,841

6,098
 
1,776,576

Jeffrey L. Edwards
Class B
4,855,765

635

90
 
140,573

Gregory K. Hinckley
Class B
4,855,765

635

90
 
140,573

Alice N. Schwartz
Class B
4,848,764

7,630

96
 
140,573

Norman Schwartz
Class B
4,848,484

7,910

96
 
140,573

 
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2018 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:

 
Votes
Votes
Votes
Broker
For
Against
Abstaining
Non-Votes
7,192,711
1,149
1,363
-













SIGNATURES

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  
 
 
 
 
 
 
 
 
 
 
 
 
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
Date:
June 18, 2018
 
By:
/s/ Timothy S. Ernst
 
 
 
 
 
Timothy S. Ernst
 
 
 
 
 
Executive Vice President, General Counsel and Secretary